Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Preparing Immunocompromised Patients for Risks of Traveling Abroad

Susan Bernstein  |  September 15, 2015

Summer is a season for travel, so if your immunocompromised patients plan to journey to regions where there are outbreaks of infections, such as chikungunya, tuberculosis, typhoid, yellow fever or other diseases, communication and preparation may prevent serious health events. “The world teems with disease-causing organisms, and almost every infection is more serious in the…

Filed under:Conditions Tagged with:ClinicalDiseaseoutbreakspatient carerheumatologistsrisk

Cardiovascular Risk in Tocilizumab Therapy for RA

Kathy Holliman  |  September 15, 2015

Observation and research have confirmed that patients with rheumatoid arthritis (RA) are at greater risk of cardiovascular disease than their peers of similar age and gender, and that traditional risk factors and chronic inflammation associated with RA apparently play a significant role in that risk. However, predicting which patients with rheumatoid arthritis are at greater…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Cardiovascular diseasepatient careRheumatoid arthritisrisktocilizumabTreatment

Guselkumab Studied to Treat RA, Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  September 15, 2015

Guselkumab Studied to Treat RA & Plaque Psoriasis Guselkumab (GUS) is a subcutaneously administered monoclonal antibody that targets interleukin (IL) 23.1 It is being investigated in a Phase 2 study to treat rheumatoid arthritis (RA) and moderate to severe plaque psoriasis (PsA). On June 11, 2015, at the 2015 meeting of the European League Against…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Biosimilarsclinical trialsDrugsguselkumaboutcomeplaque psoriasisRheumatoid arthritisrheumatologySafety

EULAR 2015: Problems with Biomarkers

Thomas R. Collins  |  September 15, 2015

ROME, Italy—The traditional approach to trials to assess new biomarkers and related treatments has largely been inefficient, and a better strategy is needed to make stratified treatment available for patients more quickly, an expert said at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR). Mahesh Parmar, PhD, director of the Medical…

Filed under:ConditionsDrug UpdatesMeeting Reports Tagged with:Biomarkersoncologypatient careTreatmenttrial

EULAR 2015: Imaging in Rheumatology

Thomas R. Collins  |  September 15, 2015

ROME, Italy—The explosion of imaging technology has made it more important than ever to establish a standardized way in which imaging can and should be used in clinical practice, an expert said in a session at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR). Marie-Antonietta d’Agostino, MD, PhD, professor of rheumatology…

Filed under:ConditionsMeeting ReportsRheumatoid Arthritis Tagged with:imagingMRIoutcomepatient carerheumatologyTreatmentUltrasound

Juvenile Idiopathic Arthritis: Parents Discuss Challenges, Support Rheumatologists Can Offer

Kathy Holliman  |  September 15, 2015

One parent wishes that she could have consulted a crystal ball at the beginning of her daughter’s illness to have “some kind of idea of what we were in for. There are so many stages of letting go of the idea of what your little kid is in for in life, what they are going…

Filed under:EthicsProfessional Topics Tagged with:education and trainingEthicspatient carerheumatologists

Self-Monitoring of RA Treatment May Lead to Fewer Office Visits

Reuters Staff  |  September 5, 2015

NEW YORK (Reuters Health)—Self-monitoring of methotrexate therapy may curb healthcare utilization in rheumatoid arthritis (RA) and psoriatic arthritis, according to a new trial. The study indicates “that this novel model of care led to significant reductions in outpatient visits to the (clinical nurse specialist) and a reduction in visits to the GP, while maintaining the…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Disease-modifying antirheumatic drugs (DMARDs)Methotrexatepatientpatient managementRheumatiod arthritis

Can We Get Closer to a Cure for RA?

Marc Feldmann & Ravinder N. Maini  |  September 1, 2015

Despite new therapeutics, progress for RA patients has virtually stalled over the past 10 years. In this article, the authors discuss many options to advance to a cure and the evidence for them, including the combination of low-dose methotrexate and anti-TNF; targeting angiogenesis and tissue damage pathways directly; antigen-specific therapy; potential combination of TNF and IL17 blockade; and targeting inhibitory receptors and regulatory T cells.

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis & Rheumatologycombination therapycureDrugsRheumatoid Arthritis (RA)

Early, Aggressive Therapy for RA May Result in Cost Savings Long Term

Lara C. Pullen, PhD  |  August 31, 2015

By considering the long-term damage from early, aggressive rheumatoid arthritis, researchers in the UK were able to develop a model demonstrating the long-term cost effectiveness of more aggressive combination therapies v. short-term treatments…

Filed under:ConditionsRheumatoid Arthritis Tagged with:adalimumabcombination therapyDisease-modifying antirheumatic drugs (DMARDs)healthcare costMethotrexateRheumatiod arthritis

Epratuzumab Results Disappointing, but Adalimumab Promising

Michele B. Kaufman, PharmD, BCGP  |  August 19, 2015

Two Phase 3 trials have shown that epratuzumab did not meet its primary endpoints for treating SLE. Meanwhile, a Phase 3 study has shown adalimumab is effective for treating enthesitis-related arthritis in juveniles…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabenthesitis-related arthritisepratuzumabJuvenile arthritissystemic lupus erythematosus (SLE)

  • « Previous Page
  • 1
  • …
  • 73
  • 74
  • 75
  • 76
  • 77
  • …
  • 106
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences